eTable 1.
Univariable Analysis of Factors Associated with Upgrade by the American Joint Committee on Cancer 8th Edition Prognostic Staging
| Patient characteristic | ER+ DCIS |
ER– DCIS |
NET |
Primary operation |
||||
|---|---|---|---|---|---|---|---|---|
| OR (95% CI) | p Value | OR (95% CI) | p Value | OR (95% CI) | p Value | OR (95% CI) | p Value | |
| Age | ||||||||
| 18–39 y | 1 | Ref | 1 | Ref | 1 | Ref | 1 | Ref |
| 40–49 y | 0.44 (0.40–0.49) | < 0.01 | 0.67 (0.55–0.82) | < 0.01 | 0.55 (0.22–1.33) | 0.18 | 0.57 (0.53–0.61) | < 0.01 |
| 50–59 y | 0.38 (0.34–0.42) | < 0.01 | 0.45 (0.37–0.55) | < 0.01 | 0.39 (0.17–0.92) | 0.03 | 0.50 (0.47–0.54) | < 0.01 |
| 60–69 y | 0.36 (0.32–0.40) | < 0.01 | 0.35 (0.28–0.42) | < 0.01 | 0.28 (0.12–0.66) | 0.01 | 0.40 (0.38–0.44) | < 0.01 |
| 70–79 y | 0.37 (0.33–0.41) | < 0.01 | 0.32 (0.26–0.40) | < 0.01 | 0.42 (0.18–0.99) | 0.05 | 0.38 (0.35–0.41) | < 0.01 |
| 80+ y | 0.42 (0.36–0.48) | < 0.01 | 0.30 (0.23–0.39) | < 0.01 | 0.74 (0.21–1.77) | 0.50 | 0.56 (0.51–0.61) | < 0.01 |
| Race | ||||||||
| White | 1 | Ref | 1 | Ref | 1 | Ref | 1 | Ref |
| Black | 1.05 (0.98–1.12) | 0.16 | 1.31 (1.15–1.49) | < 0.01 | 1.46 (0.93–2.28) | 0.10 | 1.48 (1.41–1.55) | < 0.01 |
| Hispanic | 1.14 (1.05–1.25) | < 0.01 | 1.33 (1.13–1.57) | < 0.01 | 0.97 (0.55–1.71) | 0.93 | 1.28 (1.20–1.36) | < 0.01 |
| Asian | 1.24 (1.12–1.37) | < 0.01 | 1.45 (1.21–1.73) | < 0.01 | 0.95 (0.43–2.07) | 0.90 | 1.01 (0.93–1.09) | 0.87 |
| Charlson Comorbidity Index | ||||||||
| 0 | 1 | Ref | 1 | Ref | 1 | Ref | 1 | Ref |
| 1 | 1.10 (1.03–1.17) | 0.01 | 1.08 (0.96–1.22) | 0.20 | 0.99 (0.65–1.51) | 0.98 | 1.04 (1.00–1.09) | 0.05 |
| 2 | 1.22 (1.06–1.41) | 0.01 | 1.14 (0.89–1.47) | 0.31 | 1.39 (0.74–2.64) | 0.31 | 1.09 (0.99–1.20) | 0.05 |
| ≥ 3 | 1.32 (1.03–1.69) | 0.03 | 0.95 (0.57–1.57) | 0.83 | 2.19 (1.02–4.70) | 0.04 | 1.09 (0.93–1.27) | 0.30 |
| Insurance | ||||||||
| Private | 1 | Ref | 1 | Ref | 1 | Ref | 1 | Ref |
| Medicare | 0.89 (0.84–0.93) | < 0.01 | 0.69 (0.63–0.76) | < 0.01 | 1.36 (1.00–1.84) | 0.05 | 0.84 (0.82–0.87) | < 0.01 |
| Medicaid | 1.18 (1.07–1.30) | < 0.01 | 1.48 (1.25–1.75) | < 0.01 | 1.77 (1.07–2.94) | 0.03 | 1.32 (1.24–1.40) | < 0.01 |
| Uninsured | 1.13 (0.95–1.35) | 0.17 | 1.06 (0.78–1.44) | 0.72 | 0.53 (0.13–2.21) | 0.39 | 1.32 (1.18–1.48) | < 0.01 |
| Facility type | ||||||||
| Community | 1 | Ref | 1 | Ref | 1 | Ref | 1 | Ref |
| Comprehensive | 1.26 (1.14–1.39) | < 0.01 | 1.24 (1.04–1.49) | 0.02 | 1.54 (0.78–3.01) | 0.21 | 0.99 (0.93–1.04) | 0.65 |
| Academic | 1.40 (1.27–1.54) | < 0.01 | 1.69 (1.41–2.04) | < 0.01 | 1.68 (0.85–3.29) | 0.13 | 1.02 (0.96–1.08) | 0.56 |
| Integrated network | 1.25 (1.12–1.39) | < 0.01 | 1.48 (1.21–1.80) | < 0.01 | 1.52 (0.74–3.12) | 0.26 | 0.96 (0.90–1.02) | 0.17 |
| Histology | ||||||||
| Ductal | 1 | Ref | 1 | Ref | 1 | Ref | 1 | Ref |
| Lobular | NA | — | NA | — | 1.66 (1.18–2.35) | < 0.01 | 1.54 (1.48–1.61) | < 0.01 |
| Mixed | 0.14 (0.13–1.15) | < 0.01 | 0.08 (0.07–0.10) | < 0.01 | 1.23 (0.81–1.88) | 0.37 | 1.17 (1.11–1.22) | < 0.01 |
| cT | ||||||||
| cT1 | NA (all cTis) | Ref | NA (all cTis) | — | 1 | Ref | 1 | Ref |
| cT2 | — | — | — | — | 0.47 (0.35–0.63) | < 0.01 | 0.67 (0.64–0.70) | < 0.01 |
| Operation type | ||||||||
| BCS | 1 | Ref | 1 | Ref | 1 | Ref | 1 | Ref |
| Mastectomy | 2.82 (2.70–2.95) | < 0.01 | 2.36 (2.17–2.56) | < 0.01 | 2.80 (2.11–3.72) | < 0.01 | 2.60 (2.53–2.68) | < 0.01 |
| Operation timing | ||||||||
| < 60 d | 1 | Ref | 1 | Ref | 1 | Ref | 1 | Ref |
| 60–120 d | 1.43 (1.35–1.52) | < 0.01 | 1.32 (1.19–1.47) | < 0.01 | 0.97 (0.63–1.51) | 0.90 | 1.21 (1.16–1.27) | < 0.01 |
| > 120 d | 1.75 (1.52–2.01) | < 0.01 | 1.70 (1.30–2.21) | < 0.01 | 1.01 (0.67–1.51) | 0.98 | 1.42 (1.21–1.66) | < 0.01 |
BCS, breast-conserving surgery; cT, clinical tumor category, DCIS, ductal carcinoma in situ; ER, estrogen receptor; NET, neoadjuvant endocrine therapy; OR, odds ratio; Ref, reference.